Core Viewpoint - Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving Fulgent Genetics, Inc. and its officers or directors [1] Group 1: Investigation Details - The investigation is prompted by claims from investors of Fulgent Genetics, Inc. [1] - Investors are encouraged to contact Pomerantz LLP for more information regarding the investigation [1] Group 2: Recent Developments - On February 28, 2025, Fulgent disclosed receiving a civil investigative demand from the U.S. Department of Justice concerning potential false claims under the Uninsured Program [3] - Following this disclosure, Fulgent's stock price decreased by $0.41 per share, or 2.61%, closing at $15.28 per share on March 3, 2025 [3] Group 3: Firm Background - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of over 85 years in the field [4] - The firm has successfully recovered numerous multimillion-dollar damages awards for victims of securities fraud and corporate misconduct [4]

NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDAQ: URGN).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether UroGen and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On May 16, 202 ...

Core Insights - Pomerantz LLP is investigating claims on behalf of investors of Apple Inc. regarding potential securities fraud or unlawful business practices by the company and its officers [1] - Apple announced an indefinite delay in updates to its Siri digital assistant, impacting investor sentiment and leading to a significant drop in stock price [3] - Morgan Stanley analyst Erik Woodring lowered Apple's price target due to the delay in Siri features, which could affect iPhone upgrade cycles [4] Company Developments - Apple has postponed the release of certain Siri features that were initially expected in June 2024, now anticipated to be released in the coming year [3] - Following the announcement of the delay, Apple's stock price fell by $11.59, or 4.85%, closing at $227.48 on March 10, 2025 [3] - The stock price further declined by $11.16, or 5.05%, to close at $209.68 on March 13, 2025, after Morgan Stanley's report [5] Analyst Insights - Morgan Stanley's report indicated that approximately 50% of iPhone owners who did not upgrade to the iPhone 16 cited the delay in Siri features as a reason for their decision [4] - The lowered price target from Morgan Stanley went from $275 to $252, reflecting concerns over the impact of Siri's delays on future iPhone sales [4]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Photronics, Inc. and its officers or directors [1] Financial Performance - Photronics reported second quarter 2025 revenue of $210.99 million, a 2.8% year-over-year decline, missing consensus estimates by $1.01 million [3] - Non-GAAP earnings per share for the same quarter were $0.40, falling short of consensus estimates by $0.08 [3] - The company provided third quarter revenue guidance of $200 million to $208 million, compared to consensus estimates of $220 million [3] Stock Market Reaction - Following the financial results announcement, Photronics' stock price dropped by $3.12 per share, or 15.55%, closing at $16.94 per share on May 28, 2025 [4] Management Changes - Dr. Frank Lee resigned from his position as Chief Executive Officer of Photronics, effective immediately [3]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Luminar Technologies, Inc. and its officers or directors [1] Group 1: Company Developments - On May 14, 2025, Luminar announced the resignation of founder Austin Russell as President and CEO, as well as Chairperson of the Board, following an inquiry by the Audit Committee regarding the Code of Business Conduct and Ethics [3] - Following the announcement of Russell's resignation, Luminar's stock price dropped by $0.80 per share, representing a decline of 16.81%, closing at $3.96 per share on May 15, 2025 [3] Group 2: Legal Context - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of advocating for victims of securities fraud and corporate misconduct [4]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Schrödinger, Inc. and its officers or directors [1] Group 1: Company Developments - On May 20, 2025, Schrödinger announced the departure of its Chief Financial Officer, Geoffrey Porges, which led to a significant decline in the company's stock price by $2.03 per share, or 8.62%, closing at $21.53 per share [3] Group 2: Legal Investigation - Pomerantz LLP, a prominent firm in corporate and securities class litigation, is representing investors in the investigation concerning Schrödinger [1][4]

NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Meta Platforms, Inc. (“Meta” or the “Company”) (NASDAQ: META).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Meta and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On May 15, 2025, ...

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices involving NeuroPace, Inc. and its officers or directors [1] Group 1: Company Performance - On May 27, 2025, NeuroPace announced the preliminary one-year results of the NAUTILUS study, which evaluated the safety and effectiveness of the RNS System for treating drug-resistant idiopathic generalized epilepsy (IGE) [3] - The study did not achieve statistical significance for its primary effectiveness endpoint, which aimed to demonstrate a longer time to a second generalized tonic-clonic seizure in the active stimulation group compared to the sham stimulation group [3] - Following the announcement, NeuroPace's stock price dropped by $5.02 per share, or 28.39%, closing at $12.66 per share on the same day [3] Group 2: Legal Investigation - Pomerantz LLP is reaching out to investors of NeuroPace to gather information regarding potential claims related to securities fraud [1] - The firm has a long history in corporate, securities, and antitrust class litigation, having recovered numerous multimillion-dollar damages awards for victims of securities fraud and corporate misconduct [4]

Core Viewpoint - Elevance Health, Inc. is facing a class action lawsuit due to alleged misleading statements and failure to disclose adverse facts regarding its business operations and financial guidance during the Class Period from April 18, 2024, to October 16, 2024 [1][4]. Financial Performance - On July 17, 2024, Elevance announced an expected increase in Medicaid utilization, which led to a stock price drop of $32.21, or 5.8%, closing at $520.93 per share [2]. - On October 17, 2024, Elevance reported third quarter 2024 financial results, missing EPS consensus estimates by 13.7% and lowering its EPS guidance for 2024 by 11.3%, resulting in a further stock price decline of $52.61, or 10.6%, to close at $444.35 per share [3]. Lawsuit Details - The class action complaint alleges that Elevance's management made materially false and misleading statements and failed to disclose significant adverse facts, including the higher costs associated with sicker patients remaining on Medicaid and inadequate reflection of these costs in financial guidance [4]. - Investors who purchased Elevance common stock during the Class Period have until July 11, 2025, to file a lead plaintiff motion in the lawsuit [5].

Core Viewpoint - West Pharmaceutical Services, Inc. is facing a class action lawsuit due to significant stock price decline following disappointing revenue and earnings forecasts, attributed to operational challenges and customer losses [2][3]. Group 1: Company Performance - On February 13, 2025, West issued disappointing revenue and earnings forecasts for 2025, citing Contract Manufacturing headwinds and the loss of two major continuous glucose monitoring customers [2]. - The company's SmartDose wearable injector devices are expected to be "margin dilutive" in 2025, prompting the need for steps to improve its economics [2]. - Following the announcement, West's stock price fell by $123.17, or 38.2%, closing at $199.11 per share [2]. Group 2: Lawsuit Details - The class action lawsuit alleges that West made materially false and misleading statements throughout the class period, failing to disclose significant operational issues [3]. - Specific allegations include ongoing destocking across West's high-margin HVP portfolio and operational inefficiencies related to the SmartDose device, which was expected to be a high-margin growth product [3]. - The lawsuit claims that these margin pressures could lead to costly restructuring activities, including exiting contracts with long-standing customers in the continuous glucose monitoring sector [3].